GLP1R and stroke disorder: GLP-1 therapy was associated with lower risk of MACE (HR 0.61, 95% CI 0.49-0.76; P < 0.00001) and a reduced risk of stroke (HR 0.47, 95% CI 0.23-0.97; P = 0.036).